# RareCyte

Source: https://onco.cc/companies/rarecyte/  
OnCo record `rarecyte` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

RareCyte, in Seattle, makes two kinds of laboratory instruments: one that finds the rare tumour cells circulating in a blood sample, and one that stains a tumour slice for many proteins at once so researchers can map the cells in it.

## Summary

RareCyte develops spatial biology and liquid biopsy technologies. Its CyteFinder platform, designed for monitoring circulating tumour cells in clinical trials, can in the company's words phenotype as few as one CTC per tube of blood; in 2021 it announced a synaptophysin CTC assay for characterising treatment-resistant cancers from blood. Its Orion spatial proteomics platform images many protein markers on one tissue section, and in April 2026 it launched Orion HT, for clinical-scale high-plex biomarker programmes with 30-slide automation, and Orion LE, for panel development and translational studies, and named Neil Kennedy president. In June 2024 it raised USD 20 million from new and existing investors, co-led by Arboretum Ventures and F-Prime Capital, with Forest Road, HealthQuest Capital, 5AM Ventures, Agilent Technologies, founder Ron Seubert, Sheatree Capital and GKCC LLC.

## Fields

- Kind: Company
- Last checked: 2026-11-03
- Also known as: RareCyte, Inc.
- HQ: Seattle, WA
- Type: diagnostics
- Website: https://rarecyte.com/

## Notes

- Founding year not stated on the company pages read. Headquarters is the Seattle dateline of its releases, which also refer to its Seattle laboratories. Stage growth reflects a private company with products on sale and a 2024 financing. No regulatory clearance is claimed on the pages read.

## Sources

- Official website: https://rarecyte.com/
- USD 20 million financing, June 2024: https://rarecyte.com/news-2024.06.27.html
- Orion HT and Orion LE launch, April 2026: https://rarecyte.com/news-2026.04.20.html
- Company news: https://rarecyte.com/news.html

## Connected records

- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/)
- technologies: [Circulating tumour cell capture](https://onco.cc/technologies/ctc-capture/), [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Single-cell & spatial profiling](https://onco.cc/technologies/single-cell-spatial/), [Spatial biology instruments](https://onco.cc/technologies/spatial-biology-instruments/)
- companies: [5AM Ventures](https://onco.cc/companies/5am-ventures/), [F-Prime Capital](https://onco.cc/companies/f-prime-capital/)

---
JSON: https://onco.cc/api/v1/entities/rarecyte.json